🐢 This article contains affiliate links. We may earn a small commission at no extra cost to you. These links do not influence our editorial judgements. See the
full disclosure.
TL;DR: A small set of cellular reprogramming factors called OSK (Oct4, Sox2, Klf4) has restored vision in aged, injured animal eyes by turning back the cellular clock. The technology, developed in David Sinclair’s Harvard lab and advanced by Life Biosciences, is now in Phase 1 human trials as a gene therapy called ER-100. The rejuvenation factors are switched on by a daily oral doxycycline pill for 6 to 8 weeks. If the results translate, this could become one of the first clinically proven age-reversal therapies.
🐢 Tortoise Wisdom"This is not a supplement you can order online. It is an experimental gene therapy in early human trials — but the animal data are genuinely extraordinary."
1. Watch: David Sinclair on the first human age-reversal trial
For anyone who wants to hear the story directly from the researcher, David Sinclair has discussed this breakthrough extensively on YouTube. In “The First Human Trial of Epigenetic Reprogramming Has Started”, he explains why the FDA clearance of Life Biosciences’ ER-100 trial marked the culmination of decades of work and what it means to dose a real human being with an epigenetic restoration drug.
Additional Sinclair clips covering the vision-restoration data and OSK mechanism include “Dr David Sinclair’s Reprogramming Tech in Human Trials” and “Dr Sinclair's Co Presents Groundbreaking Data On AGE REVERSAL To RESTORE VISION Via Reprogramming”.
2. What are OSK factors?
In 2006, Shinya Yamanaka showed that four genes — later named Oct4, Sox2, Klf4 and c-Myc — could reprogram adult cells back to a stem-cell-like state. That discovery won the Nobel Prize. The problem is that full reprogramming erases cellular identity and can cause cancer, especially because c-Myc is a known oncogene.
David Sinclair’s team asked a subtler question: could a partial reset restore youthful function without wiping cellular identity? They removed c-Myc and kept the other three factors, creating the OSK cocktail. OSK does not turn a nerve cell back into a stem cell; instead, it appears to reset the epigenome enough to restore youthful gene expression while preserving the cell’s specialised role.
3. The animal proof: vision restored in mice, rats and monkeys
The landmark proof came in a 2020 Nature paper titled “Reprogramming to recover youthful epigenetic information and restore vision”. Sinclair, Lu and colleagues delivered OSK to the eyes of mice with aged retinas, crushed optic nerves and glaucoma-like damage. The results were striking:
- Retinal ganglion cells partially regressed to a younger epigenetic state.
- Axons — the long fibres that carry visual signals — regenerated.
- Vision recovered in behavioural tests.
A 2023 follow-up in Cellular Reprogramming showed sustained vision recovery in a mouse glaucoma model, suggesting the effect is not just temporary. Life Biosciences then advanced the work into non-human primates, reporting reversal of vision loss after stroke-like optic nerve injury. Moving from rodent eyes to monkey eyes is a major step toward human relevance.
4. ER-100: the gene therapy and the “pill” switch
Life Biosciences’ lead candidate is ER-100. It is not a tablet you swallow to receive the rejuvenation factors. Instead, ER-100 is a gene therapy delivered directly into the eye, usually by injection. The therapy uses a harmless viral vector to install the OSK genes into retinal cells.
Here is the clever part: the OSK genes are engineered with a genetic on/off switch controlled by the antibiotic doxycycline. The factors sit silent until the patient takes oral doxycycline for 6 to 8 weeks. The drug crosses into the eye, flips the switch, and the cells begin to reprogram. Stop the pill and the factors switch off again. This makes the therapy controllable, reversible and less risky than a permanently active reprogramming cocktail.
So when Sinclair talks about a “pill” in this context, he means the activation switch, not the therapy itself.
5. Human trials are underway
This is no longer just animal research. Life Biosciences has taken ER-100 into a Phase 1/2A clinical trial for two optic nerve diseases: open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), essentially an optic-nerve stroke. The trial is registered on ClinicalTrials.gov as NCT07290244.
In 2026, the company announced that the first patients had been dosed and that administration was well-tolerated through day 56, supporting dose escalation. For an age-reversal field that has spent years in mice, dosing blind human patients represents a historic threshold.
6. What this could mean for UK longevity science
If ER-100 works in human optic nerves, the implications extend far beyond eye disease. The same OSK reprogramming principle could eventually be applied to other aged tissues: heart, muscle, kidney, brain, skin. The eye is simply the most accessible test case because it is an enclosed, immune-privileged organ where doctors can monitor recovery directly.
For UK readers, this is still an experimental therapy. It is not available as a supplement, a private treatment or a clinic offering. Anyone claiming otherwise is misrepresenting the science. The real story is that a credible, well-funded company has moved partial epigenetic reprogramming from Harvard bench to human dosing — and that is worth paying very close attention to.
7. Risks and honest caveats
The excitement around OSK is justified, but the risks are real:
- Oncogenic potential: removing c-Myc lowers, but does not eliminate, cancer risk from reprogramming. Long-term safety data are essential.
- Immune response: viral vectors and foreign proteins can trigger immune reactions, especially with repeated dosing.
- Efficacy unknown in humans: mice and monkeys are not people. Axon regeneration that works in a rodent eye may face different barriers in human optic neuropathy.
- Doxycycline limitations: long-term antibiotic use can affect gut microbiome and bacterial resistance, so the activation strategy may need refinement.
8. CRISPR, DNA methylation editing and the wider reprogramming race
OSK gene therapy is not the only path to epigenetic rejuvenation. A parallel field called CRISPR epigenome editing is developing tools that can rewrite DNA methylation marks directly, without cutting the DNA double helix. These systems use a “dead” Cas9 protein (dCas9) fused to enzymes such as DNMT3a, which adds methyl groups, or TET1, which removes them. Because the DNA sequence itself is left intact, the approach is potentially safer than conventional gene editing.
In 2021, researchers published CRISPRoff and CRISPRon in Cell, demonstrating programmable, long-lasting gene silencing and activation by editing methylation patterns. More recently, a 2025 Nature Aging study showed that editing individual age-associated CpG sites can ripple outward and affect the genome-wide epigenetic ageing landscape — a proof of concept that precise methylation editing could one day slow biological clocks.
Life Biosciences itself is best known for OSK partial reprogramming rather than CRISPR editing, but the company has presented preclinical data at conferences such as ARDD 2025 suggesting its epigenetic restoration platform may eventually be applied to liver and other ocular diseases beyond glaucoma and NAION. The underlying idea is the same in every programme: if ageing is driven by eroded epigenetic information, then restoring that information — whether with transcription factors, small molecules or targeted methylation editors — could treat multiple diseases of ageing at once.
Other players are also racing in this space. Rejuvenate Bio has published data showing that gene therapy-mediated partial reprogramming extends lifespan and reverses age-related changes in aged mice. NewLimit is focused on reprogramming the epigenome to extend healthspan, and Altos Labs has assembled a large team to study partial cellular reprogramming in depth. Each company is betting on a slightly different delivery method, tissue target or level of reprogramming intensity.
For UK readers, the key takeaway is that OSK and CRISPR epigenome editing are complementary rather than competing technologies. OSK is the broad, gene-therapy-based “reset button” already in human trials. CRISPR methylation editing is the precision tool still being sharpened in laboratories. Both could converge on the same goal: turning back the ageing clock one cell at a time.
9. Related LongevityTortoise guides
10. Frequently asked questions
What are OSK factors?
OSK is the combination of three transcription factors — Oct4, Sox2 and Klf4. They are the Yamanaka reprogramming factors with the cancer-linked c-Myc removed, allowing a safer partial reset of cellular age.
What is Life Biosciences ER-100?
ER-100 is a gene therapy candidate that delivers the OSK rejuvenation factors into eye tissue using a viral vector. The factors stay dormant until switched on by oral doxycycline.
Has OSK reprogramming restored vision in animals?
Yes. A 2020 Nature study showed vision recovery in mice and rats with crushed optic nerves and glaucoma. Non-human primate studies later showed reversal of stroke-induced vision loss.
What is the human trial status of ER-100?
ER-100 is in a Phase 1/2A trial for open-angle glaucoma and NAION, registered as NCT07290244. The first patients have been dosed and the therapy was reported as well-tolerated through day 56.
Is the age-reversal pill a real pill?
In this context, the “pill” is doxycycline, an oral antibiotic that activates the OSK gene therapy already delivered to the eye. It is an on/off switch rather than the therapy itself.
How is this related to CRISPR and DNA methylation editing?
OSK reprogramming resets the epigenome broadly. CRISPR epigenome editing is a different, more targeted approach that can add or remove DNA methylation marks at specific sites without cutting DNA. Both aim to restore youthful gene expression.